GlassScriptPhysician profile
Michelle Engdayehu
NPI 1205292935
$788.51
in general payments reported to CMS, 2019-2025
18 companies · $453 in 2025
The $453 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $183 · 2024: $152 · 2025: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $788.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $244.98 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $65.52 | 2024-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $62.29 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.95 | 2024-2025 | |
| Amgen INC. | $44.66 | 2024-2025 | Evenity, Otezla, Repatha |
| Astellas Pharma US INC | $44.15 | 2025 | Veozah |
| Abbott Laboratories | $41.29 | 2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $40.66 | 2023-2025 | |
| Lundbeck LLC | $29.48 | 2024 | Vyepti |
| Abiomed | $21.58 | 2025 | |
| Dynavax Technologies Corporation | $21.34 | 2025 | Heplisav-B |
| Teva Pharmaceuticals USA, INC. | $18.94 | 2023 | Austedo |
| Lilly USA, LLC | $18.75 | 2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $17.76 | 2025 | Airsupra |
| Sanofi-Aventis U.S. LLC | $16.24 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $14.74 | 2025 | Capvaxive, Gardasil 9 |
| Boston Scientific Corporation | $14.03 | 2023 | Watchman Access System |
| Phathom Pharmaceuticals, INC. | $11.15 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Engdayehu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.